Perspective Therapeutics, Inc.
CATX
$3.68
$0.123.37%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 290.00K | 342.00K | 234.00K | 369.00K | 526.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 290.00K | 342.00K | 234.00K | 369.00K | 526.00K |
| Cost of Revenue | 15.66M | 13.44M | 39.43M | -- | 9.02M |
| Gross Profit | -15.37M | -13.09M | -38.96M | 369.00K | -8.49M |
| SG&A Expenses | 7.71M | 7.84M | 8.25M | 6.98M | 5.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.33M | 22.17M | 21.13M | 19.00M | 14.79M |
| Operating Income | -24.04M | -21.83M | -20.90M | -18.63M | -14.26M |
| Income Before Tax | -22.00M | -18.18M | -42.21M | -15.12M | -11.21M |
| Income Tax Expenses | -- | -- | -2.10M | -- | -- |
| Earnings from Continuing Operations | -22.00M | -18.18M | -40.11M | -15.12M | -11.21M |
| Earnings from Discontinued Operations | 514.00K | -- | -59.00K | -- | -490.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.49M | -18.18M | -40.17M | -15.12M | -11.70M |
| EBIT | -24.04M | -21.83M | -20.90M | -18.63M | -14.26M |
| EBITDA | -23.31M | -21.10M | -40.38M | -17.97M | -13.69M |
| EPS Basic | -0.29 | -0.25 | -0.57 | -0.21 | -0.18 |
| Normalized Basic EPS | -0.19 | -0.16 | -0.16 | -0.13 | -0.11 |
| EPS Diluted | -0.29 | -0.25 | -1.14 | -0.21 | -0.18 |
| Normalized Diluted EPS | -0.19 | -0.16 | -0.16 | -0.13 | -0.11 |
| Average Basic Shares Outstanding | 74.24M | 72.36M | 70.82M | 70.63M | 66.65M |
| Average Diluted Shares Outstanding | 74.24M | 72.36M | 70.82M | 70.63M | 66.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |